Trial · NCT02316171

CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON)

NCT02316171, Phase 1, Completed, Viralytics; results first posted 2019-06-17

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON). Trials, record NCT02316171. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02316171

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON)
NCT number: NCT02316171
Status: Completed
Phases: Phase 1
Enrollment: 16 participants, actual
Lead sponsor: Viralytics
Conditions: Non-muscle Invasive Bladder Cancer
Interventions: CVA21, Mitomycin C
First posted: 2014-12-12
Last updated: 2022-07-27
Other registries' IDs: eudract:2014-003938-81
Results first posted: 2019-06-17
Limitations and caveats: Small number of subjects with limited follow-up; study not designed to give any indication of efficacy. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Incidence of Dose-limiting Toxicities Treatment-related Adverse Events.	30 days from last dose	Number of Participants with Treatment-emergent adverse events. The events for each cohort of dose of CVA21 only are pooled for the analysis.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Incidence of Dose-limiting Toxicities Treatment-related Adverse Events.	30 days from last dose		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Incidence of Dose-limiting Toxicities Treatment-related Adverse Events.	CVA21		9		Participants
Incidence of Dose-limiting Toxicities Treatment-related Adverse Events.	CVA21/Mitomycin C		6		Participants

Source ClinicalTrials.gov

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	A1 - CVA21 1x10^8 TCID50	4
Overall Study	STARTED	CVA21/Mitomycin C	6
Overall Study	STARTED	A2 - CVA21 3x10^8 TCID50.	3
Overall Study	STARTED	A3 - CVA21 3x10^8 TCID50 x2	3
Overall Study	COMPLETED	A1 - CVA21 1x10^8 TCID50	3
Overall Study	COMPLETED	CVA21/Mitomycin C	6
Overall Study	COMPLETED	A2 - CVA21 3x10^8 TCID50.	3
Overall Study	COMPLETED	A3 - CVA21 3x10^8 TCID50 x2	3
Overall Study	NOT COMPLETED	A1 - CVA21 1x10^8 TCID50	1
Overall Study	NOT COMPLETED	CVA21/Mitomycin C	0

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events84

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Hematuria	Renal and urinary disorders	CVA21	5	9	5
other	Hematuria	Renal and urinary disorders	CVA21/Mitomycin C	4	6	4
other	Dysuria	Renal and urinary disorders	CVA21	5	9	5
other	Dysuria	Renal and urinary disorders	CVA21/Mitomycin C	1	6	1
other	Pollakiuria	Renal and urinary disorders	CVA21	3	9	3
other	Pollakiuria	Renal and urinary disorders	CVA21/Mitomycin C	1	6	1
other	Bladder discomfort	Renal and urinary disorders	CVA21	0	9	0
other	Bladder discomfort	Renal and urinary disorders	CVA21/Mitomycin C	1	6	1
other	Bladder disorder	Renal and urinary disorders	CVA21	1	9	1
other	Bladder disorder	Renal and urinary disorders	CVA21/Mitomycin C	0	6	0

1 to 10 of 84Source ClinicalTrials.gov

See all 84 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	CVA21	0	9
Total, all-cause mortality	CVA21/Mitomycin C	0	6
Total, other adverse events	CVA21	9	9
Total, other adverse events	CVA21/Mitomycin C	6	6
Total, serious adverse events	CVA21	1	9
Total, serious adverse events	CVA21/Mitomycin C	0	6

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
31273010	RESULT

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons3

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
CVA21 vs CVA21/Mitomycin C: Incidence of Dose-limiting Toxicities Treatment-related Adverse Events.	Trial comparisons
CVA21 vs CVA21/Mitomycin C: deaths from any cause	Trial comparisons
CVA21 vs CVA21/Mitomycin C: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02316171

GET https://conductscience.org/api/trials/v1/NCT02316171/events?page=2

API reference For AI assistants